Background {#Sec1}
==========

Delirium is a very common cause of acute cognitive change in people with advanced cancer \[[@CR1]\] and is associated with increased morbidity and mortality \[[@CR2], [@CR3]\]. Delirium is a serious and complex neurocognitive disorder characterized by acute deterioration in attention, awareness and cognition, variously affecting memory, language and visuospatial ability, orientation and perception \[[@CR4]\].

Delirium occurs in people who are medically unwell, due to the underlying disease which has put them at risk (e.g. dementia, cancer, infection, renal impairment) or intercurrent problems, and the subsequent medical treatment (e.g. surgery, medication) . Delirium can occur for any person, with those who are older, have advanced illness, and/or prior cognitive impairment most at risk \[[@CR5]\]. The prevalence of delirium in patients with advanced cancer in oncology and palliative care settings is higher than that in most other settings, including geriatrics \[[@CR1], [@CR6]--[@CR9]\]. A systematic review of palliative care patients (with 98.9% of participants with advanced cancer), reported delirium incidence rates between 3% and 45%. Delirium prevalence ranged from 13.3% to 42.3% at admission to hospital, and 25% to 62% during admission. Delirium prevalence increased up to 88% in the hours to days before death \[[@CR1]\].

The pathophysiology of delirium is poorly understood, and largely hypothetical. Current hypotheses include: neuronal ageing, neuroinflammation, oxidative stress, neuroendocrine dysregulation, disruption to the circadian rhythm, and neurotransmitter dysregulation \[[@CR10], [@CR11]\]. A reduction in glucose metabolism seen in people with delirium is a model with developing evidence \[[@CR12], [@CR13]\]. Collectively, the biological correlates of delirium are referred to as 'delirium biomarkers'. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease \[[@CR14]\]. Biomarkers are most commonly studied to investigate their correlation with a disease in order to better understand its underlying pathophysiology, and subsequently inform prevention and treatment strategies for that disease. A challenge for the field of delirium research is that correlation may exist between biomarkers of delirium and those of the patient's disease or injury which placed them at increased risk of delirium, or which precipitated it (for example sepsis or hip fracture). Such correlation should be factored into delirium biomarker research, yet rarely has been. Better understanding of the interplay between delirium pathophysiology and that of correlated conditions and diseases, for example, cancer (the focus of this review), is crucial to develop more effective prevention and treatment of delirium.

We therefore conducted a systematic review of the literature to explore the overlap between biomarkers that have been studied in delirium and biomarkers that have been studied in cancer-related syndromes. Our aim was to identify biomarkers associated with delirium and with specific clinical situations in advanced cancer (namely prognosis; cognitive impairment, anorexia cachexia, cancer pain, cancer-related fatigue, and sickness behavior); and to evaluate the nature and extent of overlap of the findings.

Methods {#Sec2}
=======

A systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[[@CR15]\] was conducted. In July 2017, two separate searches were conducted in MEDLINE, PubMed, Embase, CINAHL, CENTRAL, and Web of Science. The first was for literature of delirium biomarkers; the second was for literature of biomarkers in advanced cancer-related syndromes. Primary terms for the delirium search were: 'delirium' and 'biomarker'. Search terms for the cancer search were: 'cancer', 'neoplasms', 'metastasis', 'fatigue', 'sickness behavior', 'cancer pain', 'cachexia', and 'prognosis'. Additional terms which encompassed commonly researched biomarkers were also included. Filters in Medline were: 1: Humans; 2. English language and 3. Published from 1980 onward (when delirium was first included in the *DSM, Third Edition (DSM-III)*)*.* Search terms and filters were tailored to each subsequent database, as required. The full search strategy is provided in Additional file [1](#MOESM1){ref-type="media"}. Reference lists of included studies and relevant systematic reviews and meta-analyses identified in the search were examined for additional eligible studies.

We included English language studies published in peer-reviewed journals that reported body fluid biomarkers in adult participants with delirium, cancer prognosis or an advanced cancer-related syndrome of interest. Studies were excluded if they reported delirium tremens only; did not measure delirium using a validated tool; the sample had less than 75% of participants with advanced cancer; measured tissue, genetic or animal biomarkers, or were conducted post-mortem. Protocols and ongoing studies were also excluded. Based on the expert knowledge of the authors in both delirium and cancer, the advanced cancer-related syndromes and prognosis were chosen based on the potential biological plausibility that the pathophysiological mechanisms could overlap with that of delirium. We limited the search to advanced cancer as this is the cancer population with the highest prevalence of both delirium and the cancer-related syndromes of interest.

The following definitions were used in this review: ***Anorexia cachexia:*** A complex metabolic syndrome of involuntary weight loss associated with cancer and some other palliative conditions \[[@CR16]\].***Cancer related fatigue:*** A distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer and/or cancer treatment that is not proportional to recent activity and interferes with usual functioning \[[@CR17]\].***Cancer-related pain***: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage \[[@CR18]\].***Cancer-related cognitive impairment:*** Cognitive impairment that is commonly experienced by cancer patients and those in remission. The cognitive domains most commonly affected are memory, concentration, information processing speed and executive function \[[@CR19]\].***Sickness behaviour:*** The coordinated set of behavioural changes that develop in sick individuals during the course of an infection. Sickness behavior is also seen in other illness including cancer \[[@CR20], [@CR21]\].***Cancer prognosis:*** The likely outcome or course of the disease; the chance of recovery or recurrence. Cancer prognosis is assessed by cancer-specific survival, overall survival, progression free survival or relative survival \[[@CR22]\].

Search results were imported into Endnote X7 software, duplicates removed and then exported into Covidence^TM^ ([www.covidence.org](http://www.covidence.org/)). Two reviewers per search (IAD and AH: delirium search, IAD and MA: cancer search) independently applied eligibility criteria for both searches and examined title and abstracts. Exclusions were documented only for articles that required full-text to make a formal decision. Inter-reviewer disagreement on included studies was discussed to resolve any discrepancies, with the third reviewer consulted when required. Data extraction was conducted by one reviewer (IAD) using Excel (2016) with two other reviewers (MA and AH) providing input and oversight. Data extraction was guided by the REporting recommendations for tumor MARKer prognostic studies (REMARK) checklist \[[@CR23]\].

In the absence of a gold standard risk of bias assessment for biomarker studies, one reviewer (IAD) applied an adaptation of the REMARK checklist \[[@CR23]\] to assess the methodological quality of the included studies, with 10% verification by two other reviewers (MA and AH).

The heterogeneity of data precluded performing a meta-analysis; we therefore reported the data using a narrative synthesis approach with text and tabular summaries. The synthesis was structured according to the overlap of the biomarkers in delirium, cancer prognosis and the cancer syndromes, the biomarker type, assay used, and numbers and proportions of participants who had delirium and advanced cancer. We defined 'overlap' as any biomarker that was studied in both a delirium study and an advanced cancer syndrome study.

Results {#Sec3}
=======

The delirium search yielded 3342 articles and the cancer syndromes search 4081, giving a total of 7423 articles. An additional 25 articles were found through the hand search. After removal of 1817 duplicates and 5120 articles through title and abstract screening, we reviewed 511 full text papers and subsequently excluded 288. After initial analysis, a further 72 were excluded as they did not report a biomarker studied in delirium and advanced cancer. This resulted in a total of 151 articles included in this review: 71 reported biomarkers studied in delirium, and 80 reported biomarkers studied in a cancer syndrome or prognosis (Figure [1](#Fig1){ref-type="fig"}). Fig. 1PRISMA flow diagram of search results

The 151 studies were conducted between 1985 and 2017 in Europe (*n*=86), Asia (*n*=33), The Americas (*n*=27), Australia (*n*=2), and multiple regions (*n*=3). Studies were set in a large range of settings, with the most common in general hospital settings (*n*=111; 73%). Thirty-nine studies (26%) did not report the setting. Sample sizes ranged from 7-2456, with relatively even numbers of male and female participants (55.4% male). Ninety nine articles reported a mean age, with an overall weighted mean age of 69.3 years. Of the 37 articles that reported the median age of participants, the overall median age was 54.5 years. The overall age of participants in the remaining 15 articles was not possible to determine (Additional files [2](#MOESM2){ref-type="media"} and [3](#MOESM3){ref-type="media"}). Blood biomarkers were examined in 138 studies, 4 studies examined biomarkers in cerebrospinal fluid (CSF), 3 in urine, and 16 (11%) did not report the type of biological material. Of the studies that reported the assay technique, diverse assays were used (n=20), with Enzyme-linked immunosorbent assay (ELISA) being the most common (n=62; 58%). Forty-four studies (29%) did not report the specific assay used. Of these, 21 studies (48%) were routinely measured biomarkers **(**Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Table 1Characteristics of assays and main findings of included delirium studies\*Author and yearParticipantsEndpointsBiomarkers studiedBiological materialAssay methodCovariates accounted for in multivariate analysisResultsTotal (N)SampleTotal participants with cancer/total participants in the studyNumber of delirium with cancer/total number delirium (%)Positive association with at least one delirium endpoint \*\*Negative associationEgberts *et al.* (2017) \[[@CR24]\]86Aged ≥65 admitted to geriatricsNot measured/NRNot measured/NRDelirium presenceCRP, NLRBloodFlow cytometryAge, gender, the CCI score, CRP level, and WBC countsNLRCRPKozak *et al.* (2017) \[[@CR25]\]60Patients with acute ischemic strokeNot measured/NRNot measured/NRDelirium presenceTNF-α, IL-1β, IL-18, BDNF, NSESerumELISANo multivariate analysisNoneTNF-α, IL-1β, IL-18, BDNF, NSETomasi *et al.* (2017) \[[@CR26]\]38Patients with sepsis-associated delirium and non-sepsis associated delirium^a^Not measured/NR Not measured/NRNot measured/NRDelirium presenceIL-6, IL-8, IL-10, BDNF, VCAM-1, ICAM-1, MPO, cathepsin, PDGF-AA, PDGF-AB/BB, RANTES, PAI, NCAMPlasmaELISANo multivariate analysisIL-6, IL-10, RANTES, VCAM-1, ICAM-1, PDGF-AB/BBIL-8, MPO, BDNF, NCAM, PDGF-AA, PAI, Cathepsin DVasunilashorn *et al.* (2017) \[[@CR27]\]560Patients ≥70 undergoing major non-cardiac surgery^a^Not measured/NRNot measured/NR-Delirium incidence-Delirium duration-Delirium severityCRPPlasmaELISAAge, sex, surgicalprocedure, anesthesia route, CCI and POST-OP infectious complicationsCRPNoneChu *et al.* (2016) \[[@CR28]\]103Patients aged ≥70 admitted for acute or elective vertebral, knee, or hip surgeryNot measured/NRNot measured/NRDelirium incidenceIGF-1SerumELISAMMSE and ageNoneIGF-1Dillon *et al.* (2016) \[[@CR28]\]Entire sample (n-566); pooled sample (n=150)Dementia-free adults ≥70 years old undergoing major scheduled non-cardiac surgery^a^Advanced cancer excluded; other cancer stages NRAdvanced cancer excluded; other cancer stages NRDelirium incidenceProteomics^b^PlasmaELISANo multivariate analysisCRP (PRE-OP, PACU, POD2)CRP (PO1MO)Guo *et al.* (2016) \[[@CR29]\]572Aged ≥65 with hip fractures undergoing THA^a^Not measured/NRNot measured/NR-Delirium presence-Delirium prevalenceCRP, Alb, HbBloodNRNRCRP, Alb, HbNoneKarlicic *et al.* (2016) \[[@CR30]\]120Patients with delirium in the psychiatric ICUNoneCancer excludedLethal outcomeCRPNRNRAge, pneumonia and CRPCRPNoneNeerland *et al.* (2016) \[[@CR31]\]149Patients with acute hip fractureAdvanced cancer excluded, other cancer stages NRAdvanced cancer excluded, other cancer stages NRDelirium presenceCRP, IL-6, sIL-6RCSFELISANo multivariate analysisCRP^b^sIL-6R, IL-6**Shen*et al.*(2016)** \[[@CR32]\]140Patients ≥65 undergoing elective gastrointestinal tumor resection^a^140/140 (100)36/36 (100)-Delirium incidence-Delirium severityIGF-1, CRP, IL-6SerumELISANRIGF-1, CRP, IL-6None**Sun*et al.*(2016)** \[[@CR33]\]112Oral cancer patients^a^112/112 (100)56/56 (100)Delirium incidenceIL-6, CRP, PCT, cortisol, AB1-40BloodELISANo multivariate analysisIL-6, CRP, PCT, cortisol, AB1-40NoneYen *et al.* (2016) \[[@CR34]\]98Patients undergoing elective knee replacement surgeryNot measured/NRNot measured/NRDelirium incidenceIGF-1SerumELISAObstructive sleep apnea, IGF-1 and diabetesNoneIGF-1**Avila-Funes*et al.*(2015)** \[[@CR35]\]141Patients aged ≥70 admitted to tertiary care hospital37/141 (26.2)6/23 (26)Delirium incidenceCortisol, E2BloodRadioimmunoassayAge, BMI, comorbidity, MMSE, previous history of delirium, BUN/Cr ratio, and cortisol levelsE2Cortisol**Brum*et al.*(2015)** \[[@CR36]\]70Oncology inpatients^a^45-70 (64.2)17/17 (100)Delirium presenceBDNF, TNF-αSerumELISA + Flow cytometryNo multivariate analysisNoneBDNF, TNF-αEgberts *et al.* (2015) \[[@CR37]\]86Patients admitted to Internal Medicine and Geriatrics^a^Not measured/NRNot measured/NRDelirium presenceNP, IL-6, IGF-1PlasmaHPLCAge, gender and the CCI, and those including NP were adjusted for age, gender, CCI, tertiles of eGFR and CRPNP, IL-6, IGF-1None**Foroughan*et al****.* (2015) \[[@CR38]\]200Elderly patients admitted to general hospital18/200 (9)12/44 (27)Delirium presenceCRP, HbBloodNRNRCRP, HbNoneSkrede *et al.* (2015) \[[@CR39]\]10Patients with hip fractureNot measured/NRNot measured/NRDelirium incidenceMCP-1SerumELISANo multivariate analysisMCP-1NoneVasunilashorn *et al.* (2015) \[[@CR40]\]566Patients ≥70 undergoing major non-cardiac surgery^a^Not measured/NRNot measured/NRDelirium incidenceIL-1Β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IFN-γ, GM-CSF, TNF-α, VEGFPlasmaLuminex assayNo multivariate analysisIL-1Β, IL-2, IL-6, IL-8, IL-12, VEGF, IL-5, TNF-αGM-CSF, IFN-γ, IL-10, IL-4Alexander *et al.* (2014) \[[@CR41]\]77ICU patients requiring mechanical ventilationNot measured/NRNot measured/NR-Delirium presence-Delirium durationIL-6, IL-8, IL-10, APOESerumELISAAge, sex, APACHE III, CCI, 24-hour propofoldose, 24-hour narcotic dose, and 24-hour benzodiazepinedose.APOEIL-10, IL-8, IL-6Baranyi *et al.* (2014) \[[@CR42]\]34Patients undergoing surgery for CPB^a^Not measured/NRNot measured/NRDelirium incidencesIL-2RSerumELISANo multivariate analysissIL-2RNoneCape *et al.* (2014) \[[@CR43]\]43Patients \>60 years old with hip fractureNot measured/NRNot measured/NR-Delirium incidence-Delirium prevalenceIL-1β, IFN-γ, GFAP, IGF-1, IL-1RACSFELISAPresence of prior dementiaIL-1β, IL-1RA^c^GFAP, IFN-γ, IGF-1Capri *et al.* (2014) \[[@CR44]\]351Patients admitted for any kind of emergency or elective surgery^a^Comorbidity measured, cancer NRComorbidity measured, cancer NRDelirium presenceIL-1β, IL-2, IL-6, IL-8, IL-10, TNF-αPlasmaELISAAge, comorbidity, ADL, IADL, HADS and pre-op benzodiazepines intakeIL-6, IL-2IL-8, IL-10, IL-1β (UDL), TNF-α (UDL)Chen *et al.* (2014) \[[@CR45]\]372Patients aged ≥65 who underwent surgery for a femoral neck fracture or an intertrochanteric fracture^a^Not measured/NRNot measured/NRDelirium presenceLPPlasmaELISAAge, ASA, type of surgery and plasma leptin levelLPNoneHatta *et al.* (2014) \[[@CR46]\]29Patients aged 65-89 admitted to hospital due to an emergencyNot measured/NRNot measured/NRDelirium incidenceNK cell activity, IL-1βBloodELISANo multivariate analysisNK cell activityIL-1βKazmierski *et al.* (2014) \[[@CR47]\]113ICU patients scheduled for CABG surgery with CPBNot measured/NRNot measured/NRDelirium incidenceCortisol, IL-2, TNF-α, HCY, cobalaminSerumCLIANRCortisol, IL-2, TNF-α, HCYCobalaminRitchie *et al.* (2014) \[[@CR48]\]710Patients admitted to a Medical Acute Admission UnitNot measured/NRNot measured/NR-Delirium incidence-Delirium severityCRPNRNRNRCRPNoneRitter *et al.* (2014) \[[@CR49]\]78ICU patientsNot measured/NRNot measured/NRDelirium presenceTNF-α, STNFR-1, STNFR2, APN, IL-1β, IL-6, IL-10PlasmaELISASedation and sepsisSTNFR-1, STNFR2, IL-1βTNF-α, IL-6, IL-10Zhang *et al.* (2014) \[[@CR50]\]223ICU patientsNot measured/NRNot measured/NRDelirium presenceCRPPlasmai-CHROMATMAge, sex, APACHE II, intubation status, living alone, physical restraint, alcohol drinking, smoking, type of medical condition, and hospital LOS before ICU admissionCRPNoneCerejeira *et al.* (2013) \[[@CR51]\]101Patients ≥60 years without dementia undergoing elective hip arthroplasty^a^Not measured/NRNot measured/NRDelirium incidenceCortisol, IGF-1, CRP, IL-6, IL-8, IL-10PlasmaELISANo multivariate analysisCortisolCRP, IL-6, IL-8, IL-10, IGF-1Colkesen *et al.* (2013) \[[@CR52]\]52Patients with ACS admitted to coronary ICU^a^Not measured/NRNot measured/NRDelirium presenceCortisol, troponin I, MB-CKSerumCLIANRCortisolTroponin I, MB-CKKazmierski *et al.* (2013) a \[[@CR53]\]113ICU patients scheduled for CABG surgery with CPBNot measured/NRNot measured/NRDelirium incidenceCortisol, IL-2PlasmaCLIANRCortisol^d^, IL-2NoneKazmierski *et al.* (2013) b \[[@CR54]\]113ICU patients scheduled for CABG surgery with CPBNot measured/NRNot measured/NRDelirium incidenceIL-2, TNF-αPlasmaCLIANRIl-2, TNF-αNoneLiu *et al.* (2013) \[[@CR55]\]338Patients aged ≥60 undergoing major non-cardiac surgery^a^Not measured/NRNot measured/NRDelirium incidenceIL-6BloodELISAAge, education, history of coronary artery disease, alcoholism, PRE-OP ASA ≥ 3, PRE-OP NYHA ≥ 2, PRE-OP MMSE score ≤ 24, PRE-OP serum IL-6 ≥ 7.5 ph/ml, POST-OP serum IL-6, POST-OP VAS pain levelIL-6NonePlaschke *et al.* (2013) \[[@CR56]\]1141. Patients following heart surgery^a^2. Patients on the non-cardiac ICU^a^Not measured/NRNot measured/NRDelirium incidenceIL-6PlasmaELISANo multivariate analysisNoneIL-6Skrobik *et al.* (2013) \[[@CR57]\]99ICU patients^a^Not measured/NRNot measured/NRDrug-induced coma and deliriumTNF-α, IL-1β, IL-1RA, IL-6, IL-8, IL-10, IL-17, MIP-1B, MCP-1BloodBCAFentanyl, midazolam, CYP3A4/5, P-gp inhibitorsIL-6TNF-α, IL-17, IL-8, MCP-1, IL-1RA, MIP-1B, IL-10, IL-1βWesthoff *et al.* (2013) \[[@CR58]\]61Patients ≥75 admitted for surgical repair of acute hip fracture^a^Not measured/NRNot measured/NRDelirium incidenceEGF, eotaxin, FGF-2, Flt-3L, Fractalkine, G-CSF, GM- CSF, IFN-a2, IFN-γ, IL-1RA, IL-1α, IL-1β, IL-2, sIL-2Ra, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, IP-10, MCP-1, MCP-3, MDC, MIP-1α, MIP-1β, PDGF-AA, PDGF-AB/BB, RANTES, sCD40L, TGF-α, TNF-α, TNF-β, VEGFBlood + CSFLumbar punctures and Luminex assaysNo multivariate analysisFlt-3L, IL-1RA, IL-6EGF, eotaxin, FGF-2, Fractalkine, G-CSF, GM- CSF, IFN-a2, IFN-γ, IL-1α, IL-1β, IL-2, sIL-2Ra, IL-3, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, IP-10, MCP-1, MCP-3, MDC, MIP-1α, MIP-1β, PDGF-AA, PDGF-AB/BB, RANTES, sCD40L, TGF-α, TNF-α, TNF-β, VEGFBakker *et al.* (2012) \[[@CR59]\]201Patients undergoing cardiac surgeryNot measured/NRNot measured/NRDelirium incidenceCrePlasmaNRNRCreNoneBaranyi *et al.* (2012) \[[@CR60]\]34Patients undergoing surgery for cardiopulmonary bypass^a^Not measured/NRNot measured/NRDelirium incidenceAlb, CRPSerumNRNo multivariate analysisAlbCRPCerejeira *et al.* (2012) \[[@CR61]\]101Patients aged ≥60 undergoing elective total hip arthroplasty^a^Not measured/NRNot measured/NRDelirium incidenceIL-8, IL-1β, IL-6, IL-10, TNF-α, CRP, AChE, BuChEBloodELISA (Multiplex assay)No multivariate analysisAChE, BuCHECRP, IL-1β, TNF-α, IL-6, IL-10Girard *et al.* (2012) \[[@CR62]\]138Mechanically ventilated ICU patients^a^Not measured/NRNot measured/NRDelirium incidenceCRP, MMP-9, MPO, NGAL, sTNFR1, D-dimer, protein C, PAI-1, VWFPlasmaELISAAge, severity of illness, and severe sepsisMMP-9, Protein C, sTNF-R1CRP, MPO, NGAL, D-dimer, PAI-1, VWFOsse *et al.* (2012) \[[@CR63]\]125Patients ≥70 undergoing elective cardiac surgeryNot measured/NRNot measured/NRDelirium incidenceNP, BH4, HVA, Glu, Ser, Gly, Cit, Tau, Arg, Met, Try, Tyr, Phe, Leu, Ile, Val, Try:LNAA, Tyr:LNAA, Phe:LNAA, Phe:tyr, Cit:arg, Tau:Ser 9 metPlasmaHPLCBH4, total biopterin, HVA, ratios of Trp:LNAA, tyr: LNAA, phe: LNAA, phe: Tyr, Cit:Arg, TSM ratio; baseline CRP, plasma urea, cre, age, sex, type of surgery, acute cardiac surgical risk factors, EuroSCORE, MMSE, pre-op anxiety and depression,and chronic medical comorbidityNP, HVABH4, Glu, Ser, Gly, Cit, Tau, Arg, Met, Try, Tyr, Phe, Leu, Ile, Val, Try:LNAA, Tyr:LNAA, Phe:LNAA, Phe:tyr, Cit:arg, Tau:Ser 9 metBisschop *et al.* (2011) \[[@CR64]\]143Patients undergoing surgery for hip fractureNot measured/NRNot measured/NR-Delirium presence-Delirium severityCortisol, insulin, glucoseBloodNRSex, age, pre-existing cognitive impairment, pre-existing functional impairment, cortisol, glucose, insulin, insulin:glucoseCortisolGlucose, insulinHolmes *et al.* (2011) \[[@CR65]\]222Patients with mild to severe ADNot measured/NRNot measured/NR-Presence of sickness behaviour-Delirium incidenceIL-6, TNF-α, CRPBloodELISABaseline ADAS score, age, gender, and the presence of deliriumNoneIl-6, TNF-α, CRPLee *et al.* (2011) \[[@CR66]\]65Patients ≥65 who had undergone hip surgery^a^Not measured/NRNot measured/NRDelirium incidenceCRPBloodNRNo multivariate analysisNoneCRPMcGrane *et al.* (2011) \[[@CR67]\]87Mechanically ventilated, medical and surgical ICU patients^a^Not measured/NRNot measured/NRDelirium/coma-free daysPCT, CRPBloodTRACE Assay analysisAge, APACHE II,sedation group (dexmedetomidine vs. lorazepam), and sepsisPCTCRPMorandi *et al.* (2011) \[[@CR68]\]110^e^Mechanically ventilated medical ICU patientsNot measured/NRNRDelirium presenceIGF-1BloodRadioimmunoassayAge, severe sepsis and APACHE IIIGF-1Van der Boogaard *et al.* (2011) a \[[@CR69]\]100ICU patients^a^Not measured/NRNot measured/NRDelirium presenceTNF-α, IL-1β, IL-6, IL-8, IL-17, IL-18, MIF, IL-1RA, IL-10, MCP-1, HNP-1, CRP, PCT, Ab1-42, Ab1-40, S100B, cortisolPlasmaLuminex assay, immunologic detection, and an immunometric assayNR**Delirium vs non-delirium:** IL-8^f^, IL-10^g^, Ratio A*β*~1-42/40~, TNF-α, IL-6, MIF, IL-1RA, MCP-1, PCT, cortisol, ABN-42**Inflamed delirium vs non-inflamed delirium:** IL-8, TNF-α, IL-18, IL-1RA, MCP-1, PCT, CRP, ratio A*β*~1-40/N-40,~ ratio A*β*~N-42/40,~**Delirium vs non-delirium:** IL-1Β, IL-17, IL-18, HNP, CRP, S100B, Tau, Ratio Tau/A*β*~1-42,~ A*β*~1-42,~ A*β*~1-40,~ A*β*~N-42,~ A*β*~N-40,~ Ratio A*β*~N-42/40,~ Ratio A*β*~1-42/N-42,~ Ratio A*β*~1-40/N-40~**Inflamed delirium vs non-inflamed delirium:** IL-1β, IL-6, MIF, IL-10, cortisol, ABN-42, IL-1Β, IL-17, HNP, S100B, Tau, tau/AB1-42, Ratio Tau/A*β*~1-42,~ A*β*~1-42,~ Ratio A*β*~1-42/N-42~A*β*~1-40,~ Ratio A*β*~1-42/40,~ A*β*~N-42,~ A*β*~N-40~Van der Boogaard *et al.* (2011) b \[[@CR70]\]20ICU patientsNot measured/NRNot measured/NRDelirium presenceProteomics^h^Urine + BloodNRNo multivariate analysisCRP, CreBurkhart *et al.* (2010) \[[@CR71]\]113Patients aged ≥65 undergoing elective cardiac surgery with CPBNot measured/NRNot measured/NRDelirium presenceCRPNRNREuroSCORE, Leucocytes, CRP max, Fentanyl intraoperatively, duration of mechanical ventilation, packed RBC, and treated PONVCRPNoneMu *et al.* (2010) \[[@CR72]\]243Patients undergoing elective CABG surgeryNot measured/NRNot measured/NRDelirium incidenceCortisolSerumCLIAAge, history of diabetes mellitus, PRE-OP LVEF, PRE-OP NYHA, preop EuroSCORE score, duration of surgery, POST-OP APACHE II, serum cortisol, POST-OP LVEF, POST-OP complications (within 1 day)CortisolNonePearson *et al.* (2010) \[[@CR73]\]20Patients ≥60 with acute hip fracture awaiting surgery^a^Not measured/NRNot measured/NRDelirium presenceCortisolCSF + serumELISANo multivariate analysisCortisolNonePlaschke *et al.* (2010) \[[@CR74]\]114^i^Patients undergoing elective CABG^a^Not measured/NRNot measured/NRDelirium incidenceCortisol, IL-6PlasmaELISANo multivariate analysisIL-6, cortisolNoneTsruta *et al.* (2010) \[[@CR75]\]103ICU patients^a^Not measured/NRNot measured/NR-Delirium incidence-Delirium prevalenceCRPSerumImmunoturbidimetryAge, APACHE II, coexistence of infection, use of a mechanicalventilator and length of ICU stayCRPNoneVan Munster *et al.* (2010) \[[@CR76]\]120Patients ≥65 admitted for hip fracture surgeryNot measured/NRNot measured/NRDelirium presenceCortisol, IL-6, IL-8, S100BPlasmaCBAAge, infection, pre-existent cognitive and functional impairmentCortisol, IL-6, IL-8, S100BNoneAdamis *et al.* (2009) \[[@CR77]\]67Patients aged ≥70 admitted to elderly care unitNot measured/NRNot measured/NR-Delirium incidence-Delirium severityAPOE, IL-1α, IL-1β, IL-1RA, IL-6, TNF-α, IGF-1, IFN-γ, LIFSerumELISANo Multivariate analysisIGF-1, IFN-γ, IL-1RA,APOE, IL-1α, IL-1β, IL-6, TNF-α, LIFVan Munster *et al.* (2009) \[[@CR78]\]120Patients ≥65 admitted for hip fracture surgeryNot measured/NRNot measured/NRDelirium incidenceS100B, NSEBloodECLIANo multivariate analysisS100BNSELemstra *et al.* (2008) \[[@CR79]\]68Patients undergoing surgery for hip fractureNot measured/NRNot measured/NRDelirium incidenceCRP, IL-6, IGF-1BloodELISANo multivariate analysisNoneCRP, IL-6, IGF-1Pfister *et al.* (2008) \[[@CR80]\]16^j^Patients with sepsisNot measured/NRNot measured/NRSepsis-related delirium presenceCRP, IL-6, S-100B, cortisolSerumSolid-phaseenzyme-labelled chemiluminescent sequential immunometricassayNo multivariate analysisCRP, S100B, CortisolIL-6Rudolph *et al.* (2008) \[[@CR81]\]42Patients undergoing cardiac surgeryNot measured/NRNot measured/NRDelirium incidenceIL-1β, IL-1RA, IL-6, IFN-a, TNF-α, TNF-R1, TNF-R2, IL-2, IL-2R, IL-7, IL-12p40_p70, IL-15, IFN-γ, IP-10, IL-4, IL-5, IL-10, IL-13, MIP-1a, MIP-1b, MIG, Eotaxin, RANTES, CCL-2, IL-8, GM-CSF, IL-17, DR5SerumELISANo multivariate analysisMIP-1a, MIP-1b, MIG, Eotaxin, RANTES, CCL-2IL-1β, IL-1RA, IL-6, IFN-a, TNF-α, TNF-R1, TNF-R2, IL-2, IL-2R, IL-7, IL-12p40_p70, IL-15, IFN-γ, IP-10, IL-4, IL-5, IL-10, IL-13, IL-8, GM-CSF, IL-17, DR5Van Munster *et al.* (2008) \[[@CR82]\]98Patients ≥65 admitted for hip fracture surgeryNot measured/NRNot measured/NRDelirium presenceIL-6, IL-8, IL-12(TNF-α, IL-1β, and IL-10 excluded from analysis)PlasmaCBANo multivariate analysisIl-6, IL-8IL-12Adamis *et al.* (2007) \[[@CR83]\]164Acutely ill patients admitted to elderly care unitNot measured/NRNot measured/NR-Delirium presence-Delirium resolutionAPOE, IL-1α, IL-1β, IL-1RA, IL-6, TNF-α, IGF-1, IFN-γ, LIF, CRPSerumELISALogAPACHE II, DRS, CRP, Gender, TNF-α, IFN-g, IGF-I, IL-1RA, and possession of APOE epsilon 4 alleleIGF-1, APOE, IFNγIL-6, IL-1α, IL-1β, IL-1RA, TNF-α, LIF, CRP**de Rooij*et al.*(2007)** \[[@CR84]\]185Patients aged ≥65 admitted to the Department of Medicine18/185 (9.7)9/64 (14)Delirium presenceIL-1β, IL-6, IL-8, IL-10, TNF-α, CRPSerumCBAAge, cognitive impairment, and infectionIL-6, IL-8IL-1β, IL-10, TNF-α, CRPPlaschke *et al.* (2007) \[[@CR85]\]37ICU patientsNot measured/NRNot measured/NRDelirium presenceSAA, IL-6BloodELISANo multivariate analysis for IL-6NoneSAA, IL-6White *et al.* (2005) \[[@CR86]\]283Patients ≥75 from emergency medical admissionsNot measured/NRNot measured/NR-Delirium prevalence-Delirium incidenceCRP, Alb, AChE, BuChE, Aspirin esterase, BenzoylcholinesterasePlasmaELISANo multivariate analysisCRP, Alb, AChE, BuChE, Aspirin esterase, BenzoylcholinesteraseNoneWilson *et al.* (2005) \[[@CR87]\]100Patients ≥75 suffering from significant physical illnessNot measured/NRNot measured/NRDelirium incidenceIGF-1PlasmaCLIADepression, IGF-1 levels and IQCODE scoresIGF-1NoneBeloosesky *et al.* (2004) \[[@CR88]\]32Patients undergoing surgery for hip fractureNot measured/NRNot measured/NR-Cognition-Post-operative complications (including delirium)-Post-operative function-MortalityCRP, FBGBloodNephelometric assayUnclearCRPFBGRobertsson *et al.* (2001) \[[@CR89]\]172Patients \<80 referred to the neuropsychiatric diagnostic unit with suspected dementiaNot measured/NRNot measured/NRDelirium presenceCortisolSerumNRAge, severity of dementia and severity of deliriumCortisolNoneVan der Mast *et al.* (2000) \[[@CR90]\]296^k^Patients admitted for elective cardiac surgeryNot measured/NRNot measured/NRDelirium incidenceTry, Ile, Val, Met, Leu, Tyr, Phe, Ser, cortisolPlasmaHPLCPlasma amino acids; the ratios of Trp/oLNAA, Tyr/oLNAA, and Phe/oLNAA; albumin; cortisol; and thyroid functions.Trp, Trp:LNAACortisol, Ile, Val, Met, Leu, Tyr, Phe, SerVan der Mast *et al.* (1999) \[[@CR91]\]296Patients admitted for elective cardiac surgeryNot measured/NRNot measured/NRDelirium incidenceAlb, cortisol, 5-HT, try, phe, val, leu, Ile, try:tyr:phePlasmaHPLCAge, inclusion as an in-patient, use of nifedipine, MMSE score, GHQ score, DAL score, Albumin, ratio rT3:T3; ratio Phe:oLNAAAlb, phe: Ile, Phe:Leu, Phe:val, Phe:tyr, Phe:tryCortisol, 5-HTGustafson *et al.* (1993) \[[@CR92]\]155Stroke patientsNot measured/NRNot measured/NRDelirium presenceCortisolPlasmaRadioimmunoassayIntercept, basal plasma cortisol, paresis, age, left-sided brain lesion, sex, anticholinergic medication, post-dexamethasone plasma cortisolCortisolNoneMcIntosh *et al.* (1985) \[[@CR93]\]7Male patients admitted to hospital for elective surgeryNot measured/NRNot measured/NRDelirium incidenceCortisol, B-endorphinPlasmaRadioimmunoassayNo multivariate analysisCortisol, B-endorphinNone\* Studies with both delirium and cancer participants are bolded; red coloured biomarkers indicate significance in multivariate analysis^a^ Dementia was an exclusion criteria^b^ Only CRP is reported from this study^c^ Only between incident and prevalent delirium^d^ Pre-operative and post-operative cortisol remained significantly increased in delirium, however, after controlling for pre-operative depression, only preoperative cortisol concentration remained significant, irrespective of the cortisol level after surgery.^e^ Only 66 included in the primary analysis^f^ In inflamed patients only^g^ In non-inflamed patients only^h^Only CRP and Cre are reported^i^ Same cohort as Plaschke et al. 2007^j^ Only 16 were analysed^k^ same cohort as Van Der Mast et al. 1999Abbreviations: *5HIAA* 5-Hydroxyindoleacetic acid, *5-HT* Serotonin, *6-SMT* 6-sulfatoxymelatonin, *8-Iso PGF2a* 8-iso-prostaglandin F2α, *A1A* Alpha-1 antitrypsin, *a-1-AGP* a-1-acid glycoprotein, *AA* Anticholinergic activity, *AB1* Amyloid-B, *AChE* Acetylcholinesterase, *ACS* Acute Coronary Syndromesm, *ADAS* Alzheimer's Disease Assessment Scale, *ADL* Activities of daily living, *Ala* Alanine, *Alb* Albumin, *AD* Alzheimer's Disease, *APACHE* Acute Physiology and Chronic Health Evaluation, *APN* Adiponectin, *ANG* Angiopoietin, *APOA1* Apolipoprotein A1, *APOE*: Apolipoprotein E, *Arg* Arginine, *APS* Acute Physiology Score, *ASA* American Society of American Society of Anaesteologists Scale, *BCA* The bicinchoninic acid assay, *BDNF* Brain-Derived Neurotrophic Factor, *BH4* Tetrahydrobiopterin, *BLI* B-Endorphin-Like Immunoreactivity, *BuChE* Butyrylcholinesterase, *C3* Complement C3, *CABG* Coronary Artery Bypass Graft, *CBA* Cytometric bead array immunoassay, *CCI* Charlson Comorbidity Index, *Cit* Citrulline, *CK* Creatine Kinase, *CK-MB* Creatine Kinase-MB, *CLIA* Chemiluminescence immunoassay, *CNTN-1* Contactin-1, *CPB* Cardiopulmonary Bypass, *Cre* Creatinine, *CRP* C-Reactive Protein, *E2* Estrodiol, *FBG* Fibrinogen, *FBLN-1* Fibulin-1, *ECLIA* Electrochemiluminescence immunoassay, *EGF* Epidermal Growth Factor, *FGF-2* Fibroblast Grown Factor, *Flt-3L* FMS-like tyrosine kinase 3 ligand, *GABA* Gamma-Aminobutyric Acid, *G-CSF* Granulocyte Stimulating Factor, *GFAP* Glial Fibrillary Acidic Protein, *GHQ* General Health Questionnaire, *Glu* Glutamic acid, *Gly* Glycine, *GM-CSF* Granulocyte-Macrophage Colony-Stimulating Factor, *HADS* Hospital Anxiety and Depression Scale, *Hb* Haemoglobin, *HCY* Homocysteine, *HNP-1* Defensin, *HP* Haptoglobin, *HPLC* High-performance liquid chromatography, *HVA* Homovanillic Acid, *IADL* Instrumental activities of daily living, *ICU* Intensive care unit, *Ile* Isoleycine, *ICAM-1* Intercellular Adhesion Molecule 1, *IDO* Indoleamine 2, 3-dioxygenase, *IFN* Interferon, *IGF* Insulin- Like Growth Factor, *IL* Interleukin, *IL-1RA* Interleukin-1 Receptor Antagonist, *Ile* Isoleucine, *IP-10* Interferon gamma-induced protein 10, *IQCODE* The Informant Questionnaire on Cognitive Decline in the Elderly, *KYN* Kynurenine, *Leu* Leucine, *LIF* Leukaemia Inhibitory Factor, *LNAA* Large Neutral Amino Acids, *LOS* Length of stay, *LP* Leptin, *Met* Methionine, *MB-CK* MB-isoform of Creatinine Kinase, *MCP* Monocyte Chemotactic Protein, *MDC* Human Macrophage-derived Chemokine, *MIF* Macrophage Migration Inhibitory Factor, *MIG* Monokine induced by Gamma Interferon, *MIP* Macrophage Inflammatory Protein, *MMP-9* Matrix Metalloproteinase- 9, *MMSE* Mini-mental state examination, *MPO* Myeloperoxidase, *MT* Melatonin, *NCAM* Neural Cell Adhesion Molecule, *NGAL* Neutrophil Gelatinase-Associated Lipocalin, *NLR* Neutrophil- Lymphocyte ratio, *NK cells* Natural killer cells, *NP* Neopterin, *NR* Not reported, *NSE* Neuron Specific Enolase, *Orn* Ornithine, *NYHA* New York Heart Association, *PACU* Post-anesthesia care unit, *PAI-1* Plasminogen activator inhibitor-1, *PCT* Procalcitonin, *PDGF* Platelet- Derived Growth Factor, *Phe* Phenylalanine, *pMHPG* Plasma free 3-methoxy-4-hydroxyphenylglycol, *pNF-H* The Phosphorylated Neurofilament H, *PO1MO* 1 month post-operative, *POD2* Post-operative day 2, *PONV* Post-operative nausea and vomiting, *POST-OP* Post-operative, *PRE-OP* Pre-operative, *P-tau* Phosphorylated tau, *RANTES* Chemokine (C-C motif) ligand 5, *RBC* Red blood cell, *S100B* s100 calcium-binding protein B, *sCD40L* Soluble CD40 ligand, *Ser* Serine, *sIL-XR* Soluble IL- X receptor, *SLI* Somatostatin-Like Immunoreactivity, *sTNFR* Soluble Tumor Necrosis Factor Receptor, *Tau* Taurine, *T-tau* Total tau, *TGF-a* Transforming Growth Factor Alpha, *THA* Total Hip Arthroplasty, *TRACE* Time Resolved Amplified Cryptate Emission, *TSH* Thyroid Stimulating Hormone, *TNF* Tumor Necrosis Factor, *Trp* Tryptophan, *TRX* Thioredoxin, *Tyr* Tyrosine, *UDL* Under detection limit, *Val* Valine, *VCAM-1* Vascular Cell Adhesion protein 1, *VEGF* Vascular Endothelial Growth Factor, *vWF* Von Willebrand factor, *ZAG* Zinc-a-2-GlycoproteinTable 2Characteristics of assays and main findings of included cancer studies\*Author and yearParticipantsEndpointsBiomarkers studiedBiological materialAssay methodCovariates adjusted for in multivariate analysisResultsTotal participants (N)Cases; controlPositive association with at least one endpoint\*\*Negative associationAmano *et al*. (2017)^a^ \[[@CR94]\]1702Advanced cancer patients; no control-Anorexia-Weight loss-Fatigue-Dyspnea-Dysphasia-Edema-Pressure ulcer-ADL disabilitiesCRPNRNRAge, gender, primarytumor site, distant metastasis, chemotherapy,ECOG PS, and setting of careCRPNoneDemiray *et al*. (2017) \[[@CR95]\]87Participants with advanced cancer; healthy participants without a known chronic disease-Cachexia-Weight loss-PFS-OSLP, resistinSerumELISANRLPMultivariate results NRResistin\*Multivariate results NRFogelman *et al*. (2017) \[[@CR96]\]69Participants with advanced cancer; healthy controls with no cancer diagnosisEither 10% weight loss or death at 60 days from the start of therapyAPN, bFGF, CXCL-16, FSN, Ghrelin, IGF-1, IL-1β, IL-6, IL-8, Klotho, LP, MCP-4, MK, MSTN, PIF, sTNFR1, sTNFR2, TARC, TNF-α, VEGF, ZAGNRNRSmoking status, best response, pain, difficulty swallowingMK, IL-1β, CXCL- 16, IL-6, IL-8, TNF-αMultivariate results NRAPN, bFGF, FSN, Ghrelin, IGF-1, Klotho, LP, MCP-4, MSTN, MK, PIF, sTNFR1, sTNFR2, TARC, VEGF, ZAGMultivariate results NRLuo *et al*. (2017) \[[@CR97]\]217Participants with advanced cancer; no control-PFS-OSFBG, CA-125, NLR, PLRSerum + PlasmaNRNRFBGCA-125, NLR, PLRPaulsen *et al*. (2017) \[[@CR98]\]49Participants with cancer; no control-Pain-Appetite-FatigueCRP, ESR, sTNF-R1, IL-1RA, IL-6, MCP-1, IL-18, MIF, TGF-β1SerumELISA (multiplex assay)Sex, BMI and agesTNF-r1, MCP-1, MIF, CRP, IL-6, IL-1RAIL-18, TGF-β 1, ESRAmano *et al*. (2016) \[[@CR99]\]1511Advanced cancer patients; no control-Survival rate-Mortality rateCRPPlasmaLatex-enhanced immunoturbidimetric assayAge, gender, primary tumor site, distant metastasis, chemotherapy, ECOG PS, and setting of careCRPNoneBye *et al*. (2016) \[[@CR100]\]60Participants with advanced cancer; healthy controls with normal weight-Cachexia-SurvivalIL-10, IFN-γ, LP, APN, TNF-α, IL-6, IGF-1SerumELISANo multivariate analysisIL-6IL-10, IFN-γ, TNF-α, APN, IGF-1Mitsunga *et al*. (2016) \[[@CR101]\]421Participants with advanced cancer with low, intermediate and high CRP levelsOSCRP, NLRBloodELISA (Multiplex assay)**Retrospective cohort:** Sex, age, ECOG-PS, UICC stage, CA 19-9, prognostic CRP classification; **Prospective cohort**: Sex, age, ECOG-PS, UICC stage, CA 19-9, NLR classification, mGPS, prognostic CRP classificationCRP, NLRNoneMorgado *et al*. (2016) \[[@CR102]\]49Participants with advanced cancer and fatigue with and without weight loss-Weight loss-FatigueHb, LDH, Alb, CRP, CreSerum + UrineNRNo multivariate analysisAlb, CRPHb, LDH, CreRodrigues *et al*. (2016) \[[@CR103]\]51Participants with advanced cancer; no controlFatigueIL-1, IL-6, TNF-α, α-1-AGP, GPS (Alb+CRP)BloodNRNo multivariate analysisTNF-α, GPS (Alb+CRP)NoneSrdic *et al*. (2016) \[[@CR104]\]100Participants with advanced cancer with and without cachexia-Cachexia-Chemotherapy toxicity-SurvivalCRP, IL-6, Alb, HbNRThe Bromocresol Purple methodNRCRP, IL-6, Alb, HbNoneWu *et al*. (2016) \[[@CR105]\]55Participants with advanced cancer; no control-OS-PFSNLR, PLR, ALP, LDHBloodNRNRPLR**,** NLR, LDHALPBilir *et al*. (2015) \[[@CR106]\]80Participants with advanced cancer and cachexia; healthy controls with no known chronic disease or weight loss-OS-CachexiaIl-1β, IL-1α, IL-6, TNF-α, orexin-A, galanin, TWEAK, TRAF-6, NPY, CRP, Testosterone, Alb, LDHSerumELISANRCRP, TRAF-6, Alb, LDH, IL-1a, IL-6, TNF-α, TWEAK, orexin-A, NPY, testosteroneIL-1β, galaninMiura *et al*. (2015) \[[@CR107]\]79Participants with advanced cancer; no control-Body composition-FatigueIL-6SerumELISA (multiplex assay)NRIL-6NoneMiura *et al*. (2015) b \[[@CR108]\]1160Participants with advanced cancer; no controlSurvivalmGPS (Alb+CRP)NRNRPrimary tumor site, age and gendermGPS (Alb+CRP)NoneBarrera *et al*. (2014) \[[@CR109]\]135Participants with advanced cancer; healthy controls-Quality of life (fatigue, PS, hyporexia, BMI)-SurvivalIL-31, IL-33, IL-27, IL-29, IL-1β, IL-2, IL-6, IL-8, IL-12p70, IL-17A, IFN-γ, TNF- α, IL-4, IL-10PlasmaCBANo multivariate analysisIL-6, IL-8, IFN-γ, IL-33, IL-10, IL-29^b^, IL-12p70^b^, IL17a^b^IL-31, IL-27, IL-1β, IL-2, TNF-α, IL-4Blakely *et al*. (2014) \[[@CR110]\]50Participants with advanced cancer with normal CRP and elevated CRP-OS-Mortality rate-gastrointestinal obstruction-Pain-Bleeding-Other symptoms (NR)-Major complicationsCRPSerumNRNRCRPNoneFujiwara *et al*. (2014) \[[@CR111]\]21Participants with advanced cancer with and without cachexiaCachexiaLP, IL-6, TNF-αSerumELISANo multivariate analysisLP, IL-6, TNF-αLindemann *et al*. (2014) \[[@CR112]\]218Participants with advanced cancer; no control-Survival-Weight lossCRP, AlbPlasmaImmune-turbidimetryNo multivariate analysisCRP, AlbNoneMondello *et al*. (2014) \[[@CR113]\]170Participants with advanced cancer; healthy controls-Surviva-CachexiaLP, ghrelin, obestatinSerumELISAAge, ghrelin, obestatin, leptin, metastaticdisease and chronic kidney diseaseLP, Ghrelin, obestatinNoneMoriwaki *et al*. (2014) \[[@CR114]\]62Patients with advanced cancer with GPS 0, GPS 1 or GPS 2OSGPS (Alb+CRP), ALP, LDH, Bilirubin, CEA, CA 19-9NRNRGPS, median ALP, median LDH, number of metastatic organs, liver metastasis, peritoneal metastasis, other metastasisGPS (Alb+CRP)ALP, Bilirubin, LDH, CEA, CA 19-9Szkandera *et al*. (2014) \[[@CR115]\]474Participants with cancer; no controlCancer-specific survivalCRP, NLR, PLRPlasmaNRAge, gender, tumour grade, tumour stage,administration of chemotherapy, surgical resection, NLR, PLR,bilirubin levels and plasma CRP levelsCRP, NLRPLRZhang *et al*. (2014) \[[@CR116]\]200Participants with cancer; no control-Fatigue-Chemotherapy adverse effectsTNF-α, IL-1 α, IL-1 β, 17-HCSPlasma + urineELISANo multivariate analysisTNF-α, IL-1α, IL-1β17-HCSJafri *et al*. (2013) \[[@CR117]\]173Participants with advanced cancer with high inflammation and with low inflammation-PFS-OSALI (Alb+NLR)SerumNRSex, race, PS and histologyALI (Alb+NLR)NoneLaird *et al*. (2013) \[[@CR118]\]1466Participants with advanced cancer with low and high CRP levels-Symptoms of the EOTC (pain, appetite loss, cognitive function, dyspnea, fatigue, physical function, role function, social function, QoL, nausea/vomiting, diarrhea, sleep, constipation)-SurvivalCRPBloodNRNo multivariate analysisCRPNoneLaird *et al*. (2013) b \[[@CR119]\]2456Participants with advanced cancer; no control-Symptoms of the EOTC (pain, appetite loss, cognitive function, dyspnea, fatigue, physical function, role function, social function, QoL, nausea/vomiting, diarrhea, sleep, constipation)-SurvivalmGPS (Alb+CRP)BloodNRNRmGPS (Alb+CRP)NonePaiva *et al*. (2013) \[[@CR120]\]223Participants with cancer with and without fatigue-Fatigue-OSCRP, Hb, LDH, AlbBloodNRAge, KPS, type of treatment, breast cancer, upper gastrointestinal cancer, head and neck cancer, lower gastrointestinal cancer, lung cancer, urologic cancer, and CRPCRP, Hb, LDH, Alb, WBCNoneSuh *et al*. (2013) \[[@CR121]\]98Participants with advanced cancer; no controlSurvivalIL-6, TNF-αPlasmaELISA (multiplex assay)Gender (male), fatigue (BFI-K score), ECOG (3-4), IL-6 (high, ≥9.06 pg/mL)IL-6TNF-αDe Raaf *et al*. (2012) \[[@CR122]\]92Participants with advanced cancer; cancer survivorsPhysical and mental fatigueCRP, IL-1-RA, NP, IL-6 and IL-8PlasmaCBANo multivariate analysisCRP, IL-6, IL-1-ra, NPIL-8Gioulbasanis *et al*. (2012) \[[@CR123]\]114Participants with advanced cancer with malnutrition, with a risk of malnutrition, and who were well nourished-Nutritional status (cachexia)-SurvivalIL-8PlasmaCLIAPS, histology, BMI, gender, age, smoking status, weight loss historyIL-8NoneGulen *et al*. (2012) \[[@CR124]\]88Participants with advanced cancer with and without weight loss; age- and sex-matched controlsWeight loss (\>5%)LP, APN, TNF-α, CRPSerumELISANo multivariate analysisLPAPN, TNF-α, CRPHeitzer *et al*. (2012) \[[@CR125]\]65Advanced cancer patients with cancer pain; healthy controls without painPain intensityIL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, TNF-α, TNF-β, IFN-γ, IL-1α, IL-7, IL-13, IL-18, MCP-1, MIP-1a, MIP-1B, OPGSerumELISANIUnclearUnclearMinton *et al*. (2012) \[[@CR126]\]720Participants with advanced cancer with and without fatigueFatigueCRP, Alb, HbBloodNRHb, current treatment with chemo, QOL score, depression, pain dyspnoea, cognitive function, insomnia and loss of appetiteCRP, Alb, HbNonePartridge *et al*. (2012) \[[@CR127]\]102Patients with advanced cancer with GPS 0, GPS 1 or GPS 2 ; no controlSurvivalmGPS (Alb+CRP)BloodNRSex, primary cancer site, age, Hb and WBCmGPS (Alb+CRP)NonePond *et al*. (2012) \[[@CR128]\]220Participants with advanced cancer; no control-OS-PFSCRPNRNRNRCRPNoneWang *et al*. (2012) \[[@CR129]\]177Participants with cancer; no controlSurvivalCRP, Alb, mGPS (Alb+CRP), NLRNRNRPS, pretherapeutic weight, WBC, neutrophil count, NLR, CRP, mGPS, PI, the 7^th^ TNM staging, surgery, degree of differentiation, palliate chemotherapyCRP, mGPS (Alb+CRP), NLRAlbAydin *et al*. (2011) \[[@CR130]\]61Advanced cancer patients; no controlSurvivalCRP, Alb, TFNSerumNephelometric assayNo multivariate analysisCRP, Alb, TFNNoneDev *et al*. (2011) \[[@CR131]\]77Participants with advanced cancer; no controlSymptom distress (pain, fatigue, nausea, depression, anxiety, drowsiness, appetite, well-being, dyspnea, sleep)CortisolSerumNRNRCortisolNoneGioulbasanis *et al*. (2011) \[[@CR132]\]115Participants with advanced cancer with malnutrition, with a risk of malnutrition, and who were well nourished-Nutritional status (cachexia)-SurvivalAlb, CRP, ghrelin, LP, APN, IGF-1PlasmaRadioimmunoassayNumber of metastatic sites, PS, weight loss \<5%, MNA groups, age, and major histological typeCRP, LP, AlbGhrelin, APN, IGF-1Hwang *et al*. (2011) \[[@CR133]\]402Participants with cancer; no control-PFS-OSAlb, CRPSerumLatex turbidimetric immunoassayPeritoneal metastasis, bone metastasis, albumin, CRP, ECOG PS, GPSAlb, CRPNoneKwak *et al*. (2011) \[[@CR134]\]90Participants with advanced cancer; no controlFatigueIL-6, TNF-αBloodNRBFI score, age, gender, BMI, blood pressure, heart rate, cancer site, previous treatment, comorbidity, medication, pain score, sleep disorder, dyspnea,ECOG PS, WBC, Hb, BUN, creatinine, albumin, AST, ALT, total bilirubin, CRP, IL-6, and TNF-αNoneIL-6, TNF-αLee *et al*. (2011) \[[@CR135]\]126Participants with advanced cancer; no control14 day mortalityCRPSerumNRCRP, chemotherapy, age, dyspnea, altered mental status, hypotension, and leukocytosisCRPNoneScheede-Bergdahl *et al*. (2011) \[[@CR136]\]83Participants with advanced cancer; no control- Clinical features of cachexia (weakness, loss of appetite, fatigue, QOL, weight loss)-SurvivalIL- 6, IL-1β, IL-8, TNF-αPlasmaBCASex, age, diagnosis, oncological treatment, CCI and medicationsIL- 6, IL-1β, IL-8, TNF-αNoneVlachostergios *et al*. (2011) \[[@CR137]\]77Participants with advanced cancer; no control-TTP-OSIGF-1, CRP, AlbSerumRadioimmunoassaySex, current smoker, albumin, IGF-1IGF-1, CRP, AlbNoneDiakowska *et al*. (2010) \[[@CR138]\]218Participants with cancer with and without cachexia; healthy blood donors; and patients with non-malignant diseases of alimentary tractCachexiaLP, CRP, IL-1, IL-6, IL-8, TNF-α, Alb, Hb.SerumELISANRLP, IL-6, Alb, TNF-αIL-1, IL-8, Hb, CRP\*Meek *et al*. (2010) \[[@CR139]\]56Participants with advanced cancer; no controlCancer-specific survivalIGF-1, IGFBP-3, CRP, mGPS (Alb+CRP), LPSerumNRBMI, cancer stage, Hb, WBC, mGPSmGPS (Alb+CRP)IGF-1, IGFBP-3, LP, CRPIshizuka *et al*. (2009) \[[@CR140]\]112Participants with advanced cancer; no controlMortalityCRP, Alb, mGPS (Alb+CRP), Neutrophil ratioSerumNRNeutrophil ratio, CA 19--9, CRP, albumin, and mGPSmGPS (Alb+CRP)NoneKarapanagiotou *et al*. (2009) \[[@CR141]\]161Participants with advanced cancer; healthy controls-Weight loss-TTP-OSGhrelin, LPSerumELISASex, age, BMI, GhrelinGhrelinMultivariate results NRLPMultivariate results NRPaddison *et al*. (2009) \[[@CR142]\]44Participants with advanced cancer; healthy controlsFatigueHb, WBC, Neutrophil, Monocyte,LymphocyteBloodNRAge, gender, time until treatment termination; and fatigueHb, WBC, Neutrophil count, monocyte countNoneTakahashi *et al*. (2009) \[[@CR143]\]26Participants with cancer cachexia; healthy controlsAnorexia (cachexia and BMI)TNF-α, IFN-γ, IL-6, IL-1RA, LP, ghrelinPlasmaELISANo multivariate analysisTNF-α, IL-6, IL-1RA, LPIFN- γ, ghrelinInagaki *et al*. (2008) \[[@CR144]\]46Participants with advanced cancer with and without fatigueFatigueIL-6PlasmaELISALogistic regression: IL-6, gender, weight and clinical fatigueMultiple regression: gender, weight, IL-6 and total score of the CFSIL-6NoneKarapanagiotou *et al*. (2008) \[[@CR145]\]152Participants with advanced cancer; healthy controls-Weight loss-TTP-OSLP, APN, resistinSerumELISASex, age, BMI, resistinResistinLP, APNSharma *et al*. (2008) \[[@CR146]\]52Participants with advanced cancer; no control-OS-ToxicityIL-1β, IL-2, IL-4, IL-5, IL-8, IL-6, IL-10, IL-12, GM-CSF, IFN-Y, TNF-α, sIL-6R, sgp130, VEGF, eotaxin, MCP-1, MIP-1α, MIP-1β, Alb, CRP, GPS (Alb+CRP)SerumNRTumour site (colonic primary), GPS, CEA, and albuminGPS (Alb+CRP), Hb, AlbCRP, IL-1β, IL-2, IL-4, IL-5, IL-8, IL-6, IL-10, IL-12, GM-CSF, IFN-Y, TNF-α, sIL-6R, sgp130, VEGF, eotaxin, MCP-1, MIP-1α, MIP-1βWeryńska *et al*. (2008) \[[@CR147]\]40Participants with advanced cancer with and without cachexia-Cachexia-Nutritional statusLPSerumELISANo multivariate analysisLPNoneRavasco *et al*. (2007) \[[@CR148]\]101Participants with cancer; no control-REE-Weight loss-Nutritional intakeIL-1RA, IL-6, TNF-α, IL-10, IFN-γ, VEGFSerumELISACancer histology and stage, nutritional intakeIL-1RA, IL-6, TNF-α, IFN-y, VEGFIL-10Richey *et al*. (2007) \[[@CR149]\]24Participants with cancer with and without cachexiaCachexiaGPS (Alb+CRP), Alb, IL-1a, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, TNF-α, IFN-γ, VEGF, GM-CSF, MCP-1, MIP-1a, MIP-1B, RANTES, FGF, Hb, CRP, CEASerumDry-slide method with the VITROS Fusion Series analyserNo multivariate analysisGPS (Alb+CRP), Alb, CEAIL-1a, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, TNF-α, IFN-y, VEGF, GM-CSF, GM-CSF, MCP-1, MIP-1a, MIP-1B, RANTES, FGF, Hb, CRP, CEASuh *et al*. (2007) \[[@CR150]\]44Participants with advanced cancer; no controlSurvivalCRPSerumNRNRCRPNoneAl Murri *et al*. (2006) \[[@CR151]\]96Breast cancer patients; no controlSurvivalCRP, Alb, GPS (Alb+CRP)NRNRGPS and treatmentCRP, GPS (Alb + CRP)NoneKayacan *et al*. (2006) \[[@CR152]\]56Participants with advanced cancer with and without cachexia; healthy smokers for the control-Cachexia-PS-SurvivalTNF-α, IL-6SerumELISANRNoneTNF-α, IL-6Ramsey *et al*. (2006) \[[@CR153]\]119Participants with advanced cancer; no control-Cancer-specific survival-Cancer-specific mortalityGPS (Alb+CRP)NRNRGPS, Hb, calcium, WBC, neutrophil count, Alb, CRPGPS (Alb+CRP)NoneDi Nisio *et al*. (2005) \[[@CR154]\]141Participants with advanced cancer; no controlSurvivalIL-6, IL-10, IFN-y, P-selectinPlasmaBCALife expectancy, WHO performance status, concomitant treatment, type of carcinoma, and histologyIL-10, IL-6, P-selectinIFN-yRich *et al*. (2005) \[[@CR155]\]80Participants with advanced cancer with good and dampened circadian rhythms-Extent of metastatic disease-PS-QOLIL-6, TGF-a, TNF-α, cortisolSerumELISANRIL-6, TGF-a, TNF-αCortisolBolukbas *et al*. (2004) \[[@CR156]\]69Participants with advanced cancer; healthy controls with stable weightWeight lossLPSerumELISANRLPNoneDe Vita *et al*. (2004) \[[@CR157]\]68Participants with advanced cancer; no control-TTP-OSIL-6SerumELISANRIl-6NoneDulger *et al*. (2004) \[[@CR158]\]54Participants with advanced cancer with and without cachexia; healthy gender- and age- matched adultsCachexiaTNF-α, IL-1β, IL-6, CRP, LP, GH, TG, insulin, glucose, triglyceride, total protein, ESRSerumSolid-phase, two-site chemiluminescent immunometricassaysNo multivariate analysisAlb, total protein, GH, TNF-α, IL-1β, IL-6, insulin, LP, ESR^b^, CRP^b^Glucose, TGElahi *et al*. (2004) \[[@CR159]\]165Participants with advanced cancer; no controlSurvivalAlb, CRPNRFluorescence polarization immunoassayNRAlb, CRPNoneJamieson *et al*. (2004) \[[@CR160]\]33Participants with advanced cancer; healthy controlsWeight lossHb, Alb, CRP, APN, LP, IL-6SerumELISANo multivariate analysisHb, Alb, CRP, APN, LP, IL-6NoneSongur *et al*. (2004) \[[@CR161]\]91Participants with advanced cancer; healthy controls-Malnutrition-SurvivalIL-6, Alb, CRP, TFN, LDHSerumNRNRIL-6, Alb, CRP, TFN, LDHNoneScott *et al*. (2003) \[[@CR162]\]106Participants with advanced cancer with and without weight loss-Weight lossHb, Alb, CRPBloodNRNo multivariate analysisHb, Alb, CRPNoneAleman *et al*. (2002) \[[@CR163]\]106Patients newly diagnosed with NSCL vs patients with no cancer-Nutritional status-SurvivalIL-6, IL-12, IL-10, IL-2, LP, α -1A, ferritin, CRP, TNF-α, s-TNFR2, s-IL-2R, IFN-γSerumCLIANRIL-6, IL-12, IL-2, sTNFR2, IFN-γ, sIL-2R, LP, α-1A, CRP, ferritinMultivariate results unclearIL-10, TNF-αMultivariate results unclearOrditura *et al*. (2002) \[[@CR164]\]85Participants with advanced cancer; healthy controls-OS-TTFIL-8, IL-10, IL-2SerumELISANRIL-10, IL-2, IL-8NoneScott *et al*. (2002) \[[@CR165]\]106Participants with advanced cancer; no controlSurvivalAlb, CRPBloodNRAge, sex, stage, histological type, weight loss, haemoglobin, albumin, CRP, KPS and EORTCV QLQ-C30 subscaleCRP, AlbNoneJatoi *et al*. (2001) \[[@CR166]\]73Participants with advanced cancer; healthy controlsAnorexia and/or weight lossNPY, LP, CCK-8SerumRadioimmunoassayNo multivariate analysisNPYLP, CCK-8Mantovani *et al*. (2001) \[[@CR167]\]58Participants with advanced cancer; normal weight healthy controls-BMI-Cachexia-ECOG PS-SurvivalLP, IL-6, TNF-αSerumELISANo multivariate analysisUnclearUnclearMantovani *et al*. (2000) \[[@CR168]\]32Participants with advanced cancer; normal weight healthy controls-cachectic symptoms (BMI)LP, IL-1a, IL-6, and TNF-αSerumELISANo multivariate analysisUnclearUnclearNenova *et al*. (2000) \[[@CR169]\]87Participants with advanced cancer; healthy controls-Cachexia-PrognosisTNF-αSerumELISANo multivariate analysisUnclearUnclearO\'Gorman *et al*. (1999) \[[@CR170]\]50Participants with advanced cancer with weight loss or weight gain; weight stable controls-Weight loss-Appetite-PS-InflammationAlb, CRPBloodNRNo multivariate analysisAlb, CRPNoneOkada *et al*. (1998) \[[@CR171]\]100Participants with cancer; healthy controlsWeight lossIL-6SerumELISANo multivariate analysisIL-6NoneWallace *et al*. (1998) \[[@CR172]\]54Participants with advanced cancer; healthy controlsWeight lossLPSerumRadioimmunoassayNo multivariate analysisLPNoneMaltoni *et al*. (1997) \[[@CR173]\]530Participants with advanced cancer; no controlSurvivalNeutrophil, lymphocyte & monocyte %, basophil + eosinophil %, Hb, TFN, Alb, total WBC, Pseudocholinesterase, proteinuria, TFN, transport ironBloodNRNo multivariate analysisNeutrophil %, lymphocyte %, total WBC, CHE, Albbasophil + eosinophil %, Hb, TFNSimons *et al*. (1997) \[[@CR174]\]21Participants with cancer and weight loss; no control-Weight loss-Body composition-Appetite-REELPPlasmaELISANo multivariate analysisLPNoneNote: Cancer prognosis was not separated from the other syndromes in the table\* Red coloured biomarkers indicate significance in multivariate analysis^a^Secondary analysis of Amano, 2016^b^In cancer vs no cancer onlyAbbreviations: *17-HCS* 17-hydroxycorticosteroids, *α-1-AGP* a-1-acid glycoprotein, *α-1A* alpha-1 antitrypsin, *Alb* Albumin, *ALP* Alkaline phosphatase, *APN* Adiponectin, *APOA2* Apolipoprotein A2, *BCA* The bicinchoninic acid assay, *bFGF* Basic fibroblast growth factor, *CA 19-9* Cancer antigen, *CBA* Cytometric bead array immunoassay, *CCK* Cholecystokinin, *CEA* Carcinoembryonic antigen, *CK* Creatine Kinase, *CLIA* Chemiluminescence immunoassay, *Cre* Creatinine, *CRP* C-Reactive Protein, *CXCL* Soluble CXC chemokine ligand, *ESR* Erythrocyte sedimentation rate, *FBG* Fibrinogen, *FSN* Follistatin, *GH* Growth Hormone, *GM-CSF* Granulocyte-Macrophage Colony-Stimulating Factor, *HA* Hyaluronic Acid, *Hb* Haemoglobin, *IGF* Insulin-Like Growth Factor, *IGFBP* Insulin-like Growth Factor Binding Protein, *IL* Interleukin, *IFN* Interferon, *LDH* Lactate Dehydrogenase, *LP* Leptin, *MCP* Monocyte Chemotactic Protein, *MIP* Macrophage Inflammatory Protein, *MK* Midkine, *NI* Not enough information, *NR* Not reported, *MSTN* Myostatin, *NLR* Neutrophil-lymphocyte ratio, *NP* Neopterin, *NPY* Neuropeptide Y, *OPG* Osteoprotegrin, *PLR* Platelet-lymphocyte ratio, *RANTES* Chemokine (C-C motif) ligand 5, *sTNFR* SolubleTumor Necrosis Factor Receptor, *Sgp130* Soluble **glycoprotein** 130, *TARC* Thymus and Activation-Regulated Chemokine, *TFN* Transferrin, *TG* Triglyceride, *TNF* Tumor Necrosis Factor, *TRAF-6* Tumor Necrosis Factor Receptor associated factor-6, *TTF* Time to treatment failure, *TWEAK* TNF-like weak inducer of apoptosis, *VEGF* Vascular Endothelial Growth Factor, *ZAG* Zn-alpha2 glycoprotein

A total of 41 biomarkers were found to be common in both delirium and advanced cancer syndrome studies. The five most commonly studied biomarkers were C-reactive protein (CRP) (n=79), interleukin (IL)-6 (*n*=58), tumor necrosis factor alpha (TNF- α) (*n*=42) IL-10 (*n*=21) and IL-8 (*n*=24). Of these, 24 biomarkers had a positive association with delirium, cancer prognosis or a cancer syndrome in at least one study. No cancer studies reported having any participants with delirium, and of the delirium studies, six reported participants with cancer. Figure [2](#Fig2){ref-type="fig"} illustrates two main populations identified from this systematic review, with the centre showing the 'true overlap' defined as studies that included participants with both delirium and cancer (n=6 studies). Fig. 2Conceptual model illustrating the 'true overlap' of delirium and advanced cancer biomarker studies. \* Cancer as a comorbidity not measured/reported \# Delirium as a concurrent illness or comorbidity not measured/reported

In two of these studies, all participants in the study had cancer; in another, 64.2% of participants had cancer; in the remaining three studies, less than 30% of all participants had cancer. In three of the studies, 100% of participants who had delirium also had cancer, in another two, 26% and 27% of the delirium cohorts had cancer, and in the remaining study 14% of the delirium participants had cancer (Table [1](#Tab1){ref-type="table"}). Although only six delirium studies reported co-existing cancer, there is still uncertainty as to how many participants in both groups of studies had both delirium and cancer. The two most common biomarkers in these six studies that reported a positive association with delirium were CRP (*n*=3) and IL-6 (*n*=3). It is unclear however whether these biomarkers were predominantly associated with delirium or the cancer, as three of the six studies grouped the delirium participants together, irrespective of their cancer comorbidity.

The quality assessment showed a large variability in the reporting of included studies. 150 (99%) studies had a clear aim statement which included their outcome of interest. One study did not report a clear aims statement \[[@CR175]\]. One hundred and nineteen studies (79%) did not explicitly state the hypothesis; however, in most (n=94; 62%) the hypothesis could be interpreted by the study aim. All 151 studies stated the participant population in detail. No study reported all elements of the assay methods in the REMARK checklist \[[@CR23]\]. One hundred and thirty one studies (87%) did not report whether assays were blinded to the study endpoint, however 59 (45%) of those studies were objective assessments. Further, 14 studies (9%) reported a power calculation to justify their sample size. Most (n=125; 83%) of studies defined all clinical endpoints examined. Ninety seven (64%) studies undertook multivariate analysis, and of these 67 (69%) described the multivariate model and the covariates included in the model, and 23 (23%) explained the rationale for inclusion of the covariates in the models. (Additional files [4](#MOESM4){ref-type="media"} and [5](#MOESM5){ref-type="media"}). Furthermore, 27 delirium studies (38%) did not report the reason for admission. Of the 44 studies that did report the reason for admission, these were predominantly for surgery- elective and acute (*n*=40). Most studies in the non-surgical population did not report a reason for admission, with the exception of 4 studies where the medical condition of interest occurred on admission (e.g stroke). See additional files [4](#MOESM4){ref-type="media"} and [5](#MOESM5){ref-type="media"} for the complete quality assessments.

The methodological quality of the assay procedures only is depicted in Figure [3](#Fig3){ref-type="fig"}, with reporting of type of biological material mostly provided but much lower frequency of reporting for other critical descriptors. Fig. 3Quality assessment graph of the assay procedures: review author's judgements about each assay domain of the REMARK checklist, presented as percentages across studies

Discussion {#Sec4}
==========

This is the first systematic review to our knowledge, to demonstrate the high degree of overlap in biomarkers in delirium, cancer prognosis and advanced cancer syndromes. This systematic review of 151 studies found that 41 biomarkers were independently investigated in studies of both delirium and prognosis/advanced cancer syndromes; with over half having a positive association in at least one study.

Biomarkers fall into three categories (though not mutually exclusive); those which present before disease onset that can help identify individuals who are most at risk of a particular disease (for example, genetic markers), those which are disease markers and as such, increase during disease progression and decrease after resolution, and thirdly, biomarker as an end-product of a disease for which levels are proportionate to 'damage' due to the disease \[[@CR176]\]. The findings of this systematic review suggest that categorization along these lines is less understood in delirium. For example, there is evidence to show that conditions such as sepsis and hip fracture cause changes in inflammatory markers \[[@CR177], [@CR178]\], however, there is little evidence about whether delirium self-propagates. Some animal model data in delirium suggests that there might be a direct impact of inflammatory markers on brain dysfunction \[[@CR179]\]. To our knowledge there was no published relationship between tumor markers and neurological brain dysfunction. Although clinical evidence suggests long term impacts on brain function, the exact pathophysiological mechanisms are poorly understood, and biomarkers to measure this are also unclear.

The issue of biomarker overlap between associated conditions has been researched in women with pre-eclampsia and polycystic ovary syndrome \[[@CR180]\], however the overlap with respect to delirium and its associated conditions has not been well addressed. Of the 71 delirium studies, only five studies sought to determine the association with the participants' common primary condition in their analysis. Tomasi et al. (2017) found that biomarkers differed between patients in the three groups in those with sepsis alone and those who developed sepsis-associated encephalopathy, or delirium, suggesting different mechanisms of sepsis-associated encephalopathy, delirium in people with sepsis, and sepsis itself. Likewise, Pfister et al. (2008) found differences in CRP, s100 calcium binding protein B (s100B) and cortisol in patients with sepsis-associated delirium, compared to non-sepsis associated delirium. In two studies, delirium in stroke was examined \[[@CR25], [@CR92]\] but these studies did not identify differences in cortisol \[[@CR92]\] or TNF- α, IL- 1β, IL-18, Brain-derived neurotrophic factor (BDNF) and Neuron specific enolase (NSE) \[[@CR25]\] between patients who developed delirium after stroke compared to those who did not develop delirium. Moreover, Sun et al. (2016) attempted to explore the overlap of biomarkers in delirium and dementia in patients with cancer, however, no multivariate analysis was undertaken, therefore results of this study are inconclusive.

Although the aim of this systematic review was to explore the overlap of biomarkers in delirium and advanced cancer syndromes, the findings highlighted a bigger problem in the methodology of delirium biomarker research. The quality assessment in this systematic review found that many of the included studies were of poor methodological quality, inadequately reported, or were influenced by potential confounding factors. A potential barrier to the complete understanding of delirium pathophysiology is the lack of guidelines for conducting and reporting delirium biomarker studies. Results from this review indicate that the absence of such guidelines has likely impeded the quality of individual studies and the overall quality of this critical field of delirium research. Reporting guidelines for delirium biomarker research are an essential step to improving methodological and reporting rigor, and will increase the potential for synthesis of future studies through meta-analyses.

Several studies have previously been performed to determine biomarkers associated with delirium, however potential confounding factors could be the underlying precipitants of delirium; ie risk factors (sepsis), or underlying conditions present (for example cancer or dementia). The top five most commonly studies biomarkers in this review were inflammatory biomarkers, namely, CRP, IL-6, TNF- α, IL-10 and IL-8. The challenge with inflammatory markers is that they are non-specific and the inflammatory pathways are similar to those implicated in other conditions such as sepsis and depression \[[@CR181], [@CR182]\]. Likewise, of the six delirium studies where there was concomitant cancer, it is very difficult to determine whether those biomarkers found were related to the cancer or the delirium itself, considering alterations in inflammatory pathways are implicated in both. Therefore, future delirium biomarker studies need to be prospectively evaluated and take into account and assess robustly other active co-morbidities such as cancer that could plausibly impact on the pathophysiological and/or biological findings. Similarly, future cancer biomarker studies must also take into account how delirium may clinically or biologically confound biomarker studies in cancer, considering the high prevalence of delirium in this population. Of the six delirium studies with cancer, three did not report the type of cancer, and of the remaining three studies, none were primary brain tumours or brain metastases. Understanding the spread of brain cancer is important in delirium studies, and is an important consideration for future delirium biomarker studies.

Majority of the studies in this review (n=98; 65%) undertook a multivariate analysis, taking into account confounding variables. Where studies only undertook univariate analysis, it is uncertain whether any observed changes in biomarkers were related to the delirium itself, or whether these changes may have been lost when adjusted for confounding factors (such as prior cognitive impairment) in a multivariate analysis. Furthermore, there is likely to be a higher proportion of participants with both delirium and cancer in both groups of studies for which this clinical information was not assessed or that were not reported. Key methodological issues which need to be addressed in future delirium studies include adjusting for confounders such as age, gender, concurrent medication, comorbidities, prior cognitive impairment, frailty and other neurological conditions. These clinical covariates must also be clearly defined and justified. Assay procedures ought to be reported in detail, including a detailed protocol of the reagents/kits used, repeatability assessments, methods of preservation and storage, assay validity, sensitivity limits of the assay and a scoring and reporting protocol. The timing of the assay is crucial in delirium studies, and the fluctuating pathophysiological processes occurring during delirium, after delirium resolution, and in those who have not yet developed delirium, must be taken into consideration, and be separated in future studies. More standardised and detailed methods of delirium biomarker studies is a crucial step in carrying out future subgroup analyses within this cohort and improving the overall understanding of delirium pathophysiology.

Limitations are that only English language and published studies were included. It is possible that articles were missed; however, two reviewers independently screened all citations derived from a search of six relevant and diverse databases, and all reference lists of included articles were also searched. Another limitation of our study is the lack of a risk of bias tool for biomarker studies, therefore we used an adaptation of tumor marker reporting guidelines, the REMARK checklist \[[@CR23]\]. Lastly, the heterogeneity of the data precluded the conduct of a meta-analysis, and precluded any firm conclusions about the biomarkers in delirium and cancer, thus, limiting the rigor of this review. Strengths of this review however, were that we undertook a systematic approach adhering to the PRISMA \[[@CR15]\] and an extensive quality assessment of the included studies was undertaken.

Conclusion {#Sec5}
==========

This review found that there is large overlap in the biomarkers in delirium and in advanced cancer-related syndromes, although because of the heterogeneity of the studies firm conclusions about the true overlap of delirium and advanced cancer syndrome biomarkers was not possible. More robust conduct and reporting of delirium biomarker studies will help to better understand the pathophysiology of delirium in the context of co-existing pathophysiology. An improved understanding of the clinical and biological associations of delirium and advanced cancer syndromes in future prospective studies will provide and inform the directions of research into delirium in people with advanced cancer.
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